Halo is a clinical-stage biotechnology company creating first-in-class, disease-modifying therapies for the treatment of inflammatory and fibrotic diseases. Our first indication is pulmonary hypertension and interstitial lung disease.
We are building a differentiated pipeline based on novel insights into how extracellular matrix (ECM) dysregulation drives disease
Our primary target is Hyaluronan (HA), a key component of the ECM
Alterations to HA are associated with a variety of conditions characterized by inflammation and fibrosis, including pulmonary hypertension, pulmonary fibrosis, and liver fibrosis
Our aim is to use cutting edge advances in research and development to optimize the modulation of hyaluronan and deliver safe and effective medicines for patients
Our lead pipeline candidate, H1614, is a reformulation of 4-methylumbelliferone, with the potential to be a first- and best-in-class hyaluronan (HA) remodeling agent for the treatment of patients with Group 3 pulmonary hypertension.
Preclinical and clinical data suggest that targeting the HA pathway can address the inflammation, fibrosis, and vascular remodeling associated with disease progression.